{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T14:08:44Z","timestamp":1790431724652,"version":"4.1.0"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Valproic acid (VPA) is a widely used antiepileptic drug with acceptable safety and efficacy in treating pediatric patients with various kinds of seizures. However, interindividual variations in plasma concentrations and treatment effects of patients with epilepsy treated with VPA are observed. This study aimed to evaluate the effects of various genetic variations on normalized plasma concentration of VPA (NCVPA) and the treatment response in Chinese children with epilepsy administered with VPA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Pediatric patients (3 months to 18 years old) with epilepsy, taking VPA therapy, were enrolled in the study. Important genetic variations of the pharmacokinetic and pharmacodynamic pathways of VPA were evaluated using the MassARRAY system (Sequenom). The associations of genetic variations with NCVPA\/drug response and the mean value of NCVPA in responsive and resistant patients were evaluated using SPSS (17.0) and Plink (1.07) software.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>A total of 111 children with epilepsy (80 responsive and 31 resistant) were enrolled. rs28898617 (UGT1A6, A &gt; G) was associated with an increase in NCVPA (\u03b2 = 5.31, 95% confidence interval = 0.78\u20139.83,<jats:italic toggle=\"yes\">P<\/jats:italic>= 0.024); therefore, patients with this variation need a lower dose of VPA. rs2279020 (GABRA1, G &gt; A) was associated with a decreased risk of developing VPA-resistant epilepsy (odds ratio = 0.42, 95% confidence interval = 0.21\u20130.84,<jats:italic toggle=\"yes\">P<\/jats:italic>= 0.014). Similar NCVPA was observed in resistant and responsive patients (<jats:italic toggle=\"yes\">P<\/jats:italic>= 0.257).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>rs28898617 (UGT1A6, A &gt; G) variation was associated with an increase in NCVPA. rs2279020 (GABRA1, G &gt; A) variation was associated with a decreased risk of developing VPA-resistant epilepsy. Resistant and responsive patients to VPA treatment had a similar mean value of NCVPA. The findings may help clinicians to adjust the dose and predict treatment effect for children with epilepsy receiving VPA treatment.<\/jats:p><\/jats:sec>","DOI":"10.1097\/ftd.0000000000000337","type":"journal-article","created":{"date-parts":[[2016,9,30]],"date-time":"2016-09-30T09:07:42Z","timestamp":1475226462000},"page":"738-743","source":"Crossref","is-referenced-by-count":23,"title":["Effects of UGT1A6 and GABRA1 on Standardized Valproic Acid Plasma Concentrations and Treatment Effect in Children With Epilepsy in China"],"prefix":"10.1097","volume":"38","author":[{"given":"Weixing","family":"Feng","sequence":"first","affiliation":[{"name":"Department of Neurology, Beijing Children's Hospital affiliated to Capital Medical University;"},{"name":"Department of Pediatrics, Beijing Tiantan Hospital, Capital Medical University;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghui","family":"Mei","sequence":"additional","affiliation":[{"name":"Pharmacy, Beijing Tiantan Hospital, Capital Medical University; and"},{"name":"Department of Clinical Pharmacology, College of Pharmaceutical Sciences, Capital Medical, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leting","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Beijing Tiantan Hospital, Capital Medical University;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazhen","family":"Yu","sequence":"additional","affiliation":[{"name":"Pharmacy, Beijing Tiantan Hospital, Capital Medical University; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weili","family":"Yang","sequence":"additional","affiliation":[{"name":"Pharmacy, Beijing Tiantan Hospital, Capital Medical University; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoqin","family":"Gao","sequence":"additional","affiliation":[{"name":"Pharmacy, Beijing Tiantan Hospital, Capital Medical University; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Wu","sequence":"additional","affiliation":[{"name":"Pharmacy, Beijing Tiantan Hospital, Capital Medical University; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Pharmacy, Beijing Tiantan Hospital, Capital Medical University; and"},{"name":"Department of Clinical Pharmacology, College of Pharmaceutical Sciences, Capital Medical, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Children's Hospital affiliated to Capital Medical University;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1046\/j.1528-1157.2002.t01-1-26901.x","article-title":"Systematic review and meta-analysis of incidence studies of epilepsy and unprovoked seizures","volume":"43","author":"Kotsopoulos","year":"2002","journal-title":"Epilepsia"},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2165\/00148581-200608020-00004","article-title":"Valproate as a mainstay of therapy for pediatric epilepsy","volume":"8","author":"Guerrini","year":"2006","journal-title":"Paediatr Drugs."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/brain\/awh726","article-title":"Natural history of treated childhood-onset epilepsy: prospective, long-term population-based study","volume":"129","author":"Sillanpaa","year":"2006","journal-title":"Brain"},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(06)68477-8","article-title":"Adult epilepsy","volume":"367","author":"Duncan","year":"2006","journal-title":"Lancet"},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs\u2013best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4103\/0028-3886.152631","article-title":"Prevalence of UGT1A6 polymorphisms in children with epilepsy on valproate monotherapy","volume":"63","author":"Jain","year":"2015","journal-title":"Neurol India."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s40291-013-0041-8","article-title":"The effect of uridine diphosphate glucuronosyltransferase (UGT)1A6 genetic polymorphism on valproic acid pharmacokinetics in Indian patients with epilepsy: a pharmacogenetic approach","volume":"17","author":"Munisamy","year":"2013","journal-title":"Mol Diagn Ther."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2133\/dmpk.DMPK-11-NT-144","article-title":"Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy","volume":"27","author":"Guo","year":"2012","journal-title":"Drug Metab Pharmacokinet."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2217\/pgs.12.78","article-title":"Functional impact and prevalence of polymorphisms involved in the hepatic glucuronidation of valproic acid","volume":"13","author":"Chatzistefanidis","year":"2012","journal-title":"Pharmacogenomics"},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/ane.12473","article-title":"Cytochrome P450 2C19 polymorphisms and valproic acid-induced weight gain","volume":"133","author":"Noai","year":"2016","journal-title":"Acta Neurol Scand."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s00228-009-0712-x","article-title":"Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling","volume":"65","author":"Jiang","year":"2009","journal-title":"Eur J Clin Pharmacol."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/epi.13011","article-title":"Clinical significance of CYP2C9-status guided valproic acid therapy in children","volume":"56","author":"Budi","year":"2015","journal-title":"Epilepsia"},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/toxsci\/kfl096","article-title":"Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1\/*1 genotype","volume":"94","author":"Kiang","year":"2006","journal-title":"Toxicol Sci."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/FPC.0b013e32835ea0b2","article-title":"Valproic acid pathway: pharmacokinetics and pharmacodynamics","volume":"23","author":"Ghodke-Puranik","year":"2013","journal-title":"Pharmacogenet Genomics."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.eplepsyres.2015.09.001","article-title":"Effects of CYP3A4\/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy","volume":"117","author":"Wang","year":"2015","journal-title":"Epilepsy Res."},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1755-5949.2012.00336.x","article-title":"ABCC2 polymorphisms and haplotype are associated with drug resistance in Chinese epileptic patients","volume":"18","author":"Qu","year":"2012","journal-title":"CNS Neurosci Ther."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/j.2042-7158.2011.01282.x","article-title":"No effect of co-administered antiepileptic drugs on in-vivo protein binding parameters of valproic acid in patients with epilepsy","volume":"63","author":"Suzuki","year":"2011","journal-title":"J Pharm Pharmacol."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.nbd.2005.12.012","article-title":"Correlation of transcriptome profile with electrical activity in temporal lobe epilepsy","volume":"22","author":"Arion","year":"2006","journal-title":"Neurobiol Dis."},{"key":"R20-20230814","first-page":"416","article-title":"ABCB1, ABCC2, SCN1A, SCN2A, GABRA1 gene polymorphisms and drug resistant epilepsy in the Chinese Han population","volume":"70","author":"Zhou","year":"2015","journal-title":"Pharmazie"},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/FPC.0000000000000000","article-title":"GABRG2, rs211037 is associated with epilepsy susceptibility, but not with antiepileptic drug resistance and febrile seizures","volume":"23","author":"Balan","year":"2013","journal-title":"Pharmacogenet Genomics."},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.seizure.2010.02.009","article-title":"Association of alpha subunit of GABAA receptor subtype gene polymorphisms with epilepsy susceptibility and drug resistance in north Indian population","volume":"19","author":"Kumari","year":"2010","journal-title":"Seizure"},{"key":"R23-20230814","doi-asserted-by":"crossref","first-page":"5457","DOI":"10.1007\/s12035-015-9457-y","article-title":"Contribution of GABRG2 polymorphisms to risk of epilepsy and febrile seizure: a multicenter Cohort study and meta-analysis","volume":"53","author":"Haerian","year":"2016","journal-title":"Mol Neurobiol."},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.seizure.2012.10.007","article-title":"GABRG2 rs211037 polymorphism and epilepsy: a systematic review and meta-analysis","volume":"22","author":"Haerian","year":"2013","journal-title":"Seizure"},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.eplepsyres.2012.06.006","article-title":"Prevalence of SCN1A mutations in children with suspected Dravet syndrome and intractable childhood epilepsy","volume":"102","author":"Wang","year":"2012","journal-title":"Epilepsy Res."},{"key":"R26-20230814","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.2217\/pgs.12.127","article-title":"SCN1A IVS5N+5 polymorphism and response to sodium valproate: a multicenter study","volume":"13","author":"Haerian","year":"2012","journal-title":"Pharmacogenomics"},{"key":"R27-20230814","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.clinthera.2008.08.011","article-title":"Drug interactions between chemotherapeutic regimens and antiepileptics","volume":"30","author":"Yap","year":"2008","journal-title":"Clin Ther."},{"key":"R28-20230814","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1038\/srep04362","article-title":"Soybean greatly reduces valproic acid plasma concentrations: a food-drug interaction study","volume":"4","author":"Marahatta","year":"2014","journal-title":"Sci Rep."},{"key":"R29-20230814","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.eplepsyres.2016.02.013","article-title":"Concentrations of carbamazepine and carbamazepine-10,11-epoxide in maternal and umbilical cord blood at birth: influence of co-administration of valproic acid or enzyme-inducing antiepileptic drugs","volume":"122","author":"Kacirova","year":"2016","journal-title":"Epilepsy Res."},{"key":"R30-20230814","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ejps.2009.09.017","article-title":"The influence of drug-drug interaction and patients' characteristics on valproic acid's clearance in adults with epilepsy using nonlinear mixed effects modeling","volume":"38","author":"Vucicevic","year":"2009","journal-title":"Eur J Pharm Sci."},{"key":"R31-20230814","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.eplepsyres.2015.04.015","article-title":"The influence of UGT2B7 genotype on valproic acid pharmacokinetics in Chinese epilepsy patients","volume":"114","author":"Sun","year":"2015","journal-title":"Epilepsy Res."},{"key":"R32-20230814","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00228-012-1277-7","article-title":"Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients","volume":"68","author":"Chu","year":"2012","journal-title":"Eur J Clin Pharmacol."},{"key":"R33-20230814","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2217\/pgs.11.64","article-title":"Association of genetic variants in six candidate genes with valproic acid therapy optimization","volume":"12","author":"Hung","year":"2011","journal-title":"Pharmacogenomics"},{"key":"R34-20230814","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/dmd.108.022426","article-title":"Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10","volume":"37","author":"Argikar","year":"2009","journal-title":"Drug Metab Dispos."},{"key":"R35-20230814","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/FTD.0000000000000012","article-title":"Influence of uridine diphosphate glucuronosyltransferase 2B7 -161C>T polymorphism on the concentration of valproic acid in pediatric epilepsy patients","volume":"36","author":"Inoue","year":"2014","journal-title":"Ther Drug Monit."},{"key":"R36-20230814","first-page":"42","article-title":"An association between the FABP2 gene polymorphism and efficacy of valproates","volume":"107","author":"Aksenova","year":"2007","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova."},{"key":"R37-20230814","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.clineuro.2010.01.002","article-title":"The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients","volume":"112","author":"Tan","year":"2010","journal-title":"Clin Neurol Neurosurg."},{"key":"R38-20230814","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1139\/Y06-085","article-title":"Effect of Ginkgo biloba extract on oxidative metabolism of valproic acid in hepatic microsomes from donors with the CYP2C9*1\/*1 genotype","volume":"85","author":"Numa","year":"2007","journal-title":"Can J Physiol Pharmacol."},{"key":"R39-20230814","doi-asserted-by":"crossref","first-page":"15419","DOI":"10.1016\/S0021-9258(17)40694-6","article-title":"The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans","volume":"269","author":"de Morais","year":"1994","journal-title":"J Biol Chem."},{"key":"R40-20230814","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.psychres.2008.05.010","article-title":"Preliminary evidence on the association between XBP1-116C\/G polymorphism and response to prophylactic treatment with valproate in bipolar disorders","volume":"168","author":"Kim","year":"2009","journal-title":"Psychiatry Res."},{"key":"R41-20230814","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/ng1235","article-title":"Impaired feedback regulation of XBP1 as a genetic risk factor for bipolar disorder","volume":"35","author":"Kakiuchi","year":"2003","journal-title":"Nat Genet."},{"key":"R42-20230814","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/epi.12585","article-title":"Final comments on the process: ILAE definition of epilepsy","volume":"55","author":"Fisher","year":"2014","journal-title":"Epilepsia"},{"key":"R43-20230814","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/epi.12550","article-title":"ILAE official report: a practical clinical definition of epilepsy","volume":"55","author":"Fisher","year":"2014","journal-title":"Epilepsia"},{"key":"R44-20230814","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"R46-20230814","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1073\/pnas.98.2.581","article-title":"High-throughput development and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption\/ionization time-of-flight mass spectrometry","volume":"98","author":"Buetow","year":"2001","journal-title":"Proc Natl Acad Sci U S A."},{"key":"R47-20230814","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/00008571-199712000-00007","article-title":"Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological implications","volume":"7","author":"Ciotti","year":"1997","journal-title":"Pharmacogenetics"},{"key":"R48-20230814","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0026-895X(25)09788-3","article-title":"Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese","volume":"46","author":"De Morais","year":"1994","journal-title":"Mol Pharmacol."},{"key":"R49-20230814","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N Engl J Med."},{"key":"R50-20230814","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1067\/mcp.2001.117367","article-title":"Genetic polymorphisms and functional characterization of the 5'-flanking region of the human CYP2C9 gene: in vitro and in vivo studies","volume":"70","author":"Shintani","year":"2001","journal-title":"Clin Pharmacol Ther."},{"key":"R51-20230814","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/00008571-200412000-00004","article-title":"Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism","volume":"14","author":"King","year":"2004","journal-title":"Pharmacogenetics"},{"key":"R52-20230814","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/FPC.0b013e3282f85e36","article-title":"Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs","volume":"18","author":"Hung","year":"2008","journal-title":"Pharmacogenet Genomics."},{"issue":"suppl 1","key":"R53-20230814","first-page":"S32","article-title":"Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian population","volume":"17","author":"Kumari","year":"2011","journal-title":"Indian J Hum Genet."},{"key":"R54-20230814","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1684\/epd.2011.0419","article-title":"Association between ABCB1 polymorphism and response to sodium valproate treatment in Malaysian epilepsy patients","volume":"13","author":"Haerian","year":"2011","journal-title":"Epileptic Disord."},{"key":"R55-20230814","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.dmpk.2015.05.002","article-title":"Polymorphisms of ABCG2, ABCB1 and HNF4alpha are associated with Lamotrigine trough concentrations in epilepsy patients","volume":"30","author":"Zhou","year":"2015","journal-title":"Drug Metab Pharmacokinet."},{"key":"R56-20230814","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.seizure.2011.04.003","article-title":"Lack of association of ABCB1 haplotypes on five loci with response to treatment in epilepsy","volume":"20","author":"Haerian","year":"2011","journal-title":"Seizure"},{"key":"R57-20230814","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.yebeh.2008.08.019","article-title":"No association of ABCB1 polymorphisms with drug-refractory epilepsy in a north Indian population","volume":"14","author":"Lakhan","year":"2009","journal-title":"Epilepsy Behav."},{"key":"R58-20230814","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/epi.12132","article-title":"A systematic review and meta-analysis of the role of ABCC2 variants on drug response in patients with epilepsy","volume":"54","author":"Grover","year":"2013","journal-title":"Epilepsia"},{"key":"R59-20230814","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2217\/pgs.11.143","article-title":"Lack of association between ABCC2 gene variants and treatment response in epilepsy","volume":"13","author":"Hilger","year":"2012","journal-title":"Pharmacogenomics"},{"key":"R60-20230814","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/cne.903590111","article-title":"GABAA-receptor heterogeneity in the adult rat brain: differential regional and cellular distribution of seven major subunits","volume":"359","author":"Fritschy","year":"1995","journal-title":"J Comp Neurol."},{"key":"R61-20230814","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3389\/neuro.02.005.2008","article-title":"Epilepsy, E\/I Balance and GABA(a) receptor Plasticity","volume":"1","author":"Fritschy","year":"2008","journal-title":"Front Mol Neurosci."},{"key":"R62-20230814","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/sj.tpj.6500203","article-title":"Gender-specific contribution of the GABA(A) subunit genes on 5q33 in methamphetamine use disorder","volume":"3","author":"Lin","year":"2003","journal-title":"Pharmacogenomics J."},{"key":"R63-20230814","doi-asserted-by":"crossref","first-page":"585","DOI":"10.4103\/0028-3886.105191","article-title":"Lack of association between rs211037 of the GABRG2 gene and juvenile myoclonic epilepsy in Brazilian population","volume":"60","author":"Gitai","year":"2012","journal-title":"Neurol India."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201612000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T22:06:21Z","timestamp":1749593181000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201612000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000337","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}